Insights

Are these 2 ASX 200 healthcare shares a buy yet? 

After a recent pull back in ASX 200 healthcare shares, could Nanosonics Ltd (ASX: NAN) and 1 other be in the buy zone today?
The post Are these 2 ASX 200 healthcare shares a buy yet?  appeared first on Motley Fool Australia. –

Healthcare shares have long been outperformers on the S&P/ASX 200 Index (ASX: XJO) and in the general sharemarket. But in recent weeks, many ASX 200 healthcare shares have faced setbacks in the wake of significant share price run ups, weaker than expected earnings and sharp selloffs.

Could these 2 ASX 200 healthcare shares be in the buy zone yet? Let’s take a look.

1. Nanosonics Ltd (ASX: NAN) 

Nanosonics has been able to trade at an eye-watering valuation on the hopes that it would become the next CSL Limited (ASX: CSL) within the ultrasound probe disinfection market. The company boasts a $1.75 billion valuation with a price-to-earnings (P/E) ratio of 180. 

Following a weak FY20 earnings report on 25 August, the Nanosonics share price has drifted 10% lower. The company delivered a 19% increase in revenue to $100.1 million while profit before tax fell to $12.4 million. This compared to $16.8 million in FY19.

In the first three quarters of the year, total revenue was up 26% on pcp. In Q4, when the main impacts of COVID-19 were experienced, revenue increased by only 1%. While Nanosonics has experienced a weak earnings period, the significant global market opportunity remains intact. The company has approximately 20% global market penetration of the ultrasound probe disinfection market.

Key geographic opportunities include North America, Europe, the Middle East and Asia. The business continues to focus on its Japan market development strategy with distribution agreements in place with five key distributors and the continued development of a China market entry strategy. Nanosonics could be a solid ASX 200 healthcare share to own for long-term investors given the significant global market opportunity at hand. 

2. Fisher & Paykel Healthcare Corp Ltd (ASX: FPH) 

The Fisher & Paykel share price has soared more than 45% this year following the tailwinds that COVID-19 has brought for its business. In its latest business update announced on 18 August, the company cited strong demand for its hospital respiratory care products with hospital hardware sales in the first four months of FY21 increasing 390% on pcp. The company is seeing that revenue by geography tends to follow the incidence of COVID-19 cases and the recent resurgence of COVID-19 cases across Europe, India and US could see further earnings tailwinds for its respiratory products. 

The business update also forecasted FY21 operating revenue to be approximately $1.61bn and net profit after tax to be within the range of $365 million to $385 million. This would represent an increase of 27-34% on FY20. I believe Fisher & Paykel could see an elevated growth trajectory for the short to medium term driven by COVID-19 related tailwinds. I believe its recent pullback could be a buying opportunity. 

Man who said buy Kogan shares at $3.63 says buy these 3 ASX stocks now

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

In this FREE STOCK REPORT, Scott just revealed what he believes are the 3 ASX stocks for the post COVID world that investors should buy right now while they still can. These stocks are trading at dirt-cheap prices and Scott thinks these could really go gangbusters as we move into ‘the new normal’.

Find out the names of our 3 Post COVID Stocks – For FREE!

*Returns as of 6/8/2020

More reading

Lina Lim has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. and Nanosonics Limited. The Motley Fool Australia has recommended Nanosonics Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Are these 2 ASX 200 healthcare shares a buy yet?  appeared first on Motley Fool Australia.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!